6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as alpha adrenergic agents
CA 2091440 C · Owner: Allergan, Inc. · Inventors: Gluchowski, Charles
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
see formula I), Compounds having alpha adrenergic activity and useful for the treatment of glaucoma, renal and gastrointestinal disorders and vasoconstrictors have formula (1) where R1, is independently H, or lower alkyl of 1 to 6 carbons; R2 is independently H, or lower alkyl of 1 to 6 carbons or the two R2 symbols jointly represent a carbonyl oxygen; R3 is H, lower alkyl of 1 to 6 carbons, O OH and OR- where, R- is lower alkyl of 1 to 6 carbons or R3 is COH or COR8, where R8 is lower alkyl of 1 to 6 carbons; R4 and R5 independently is H, Br, Cl, or lower alkyl of 1 to 6 carbons, lower alkenyl or lower alkynyl with the proviso that when the R2 groups symbolize a carbonyl oxygen then R4 and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 10, 1991 and granted November 11, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 10, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 10, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.